<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957229</url>
  </required_header>
  <id_info>
    <org_study_id>2009-026</org_study_id>
    <secondary_id>SHH-4685s</secondary_id>
    <nct_id>NCT00957229</nct_id>
  </id_info>
  <brief_title>To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)</brief_title>
  <acronym>GDC-0449</acronym>
  <official_title>A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to reduce the number of new surgically eligible BCCs by 50%&#xD;
      appearing during month 3-18 of medication ingestion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, 18 month, double blind, randomized placebo-controlled, two arm&#xD;
      multicenter clinical study design. During the 18-month treatment period, the safety and&#xD;
      chemopreventive efficacy of 150 mg/day GDC-0449 versus placebo will be assessed, and include&#xD;
      evaluations of the skin at monthly intervals for the first three months and then every 3&#xD;
      months for the next 15 months. Removal of new surgically eligible BCCs (SEBs) will be done by&#xD;
      primary skin care physicians (PSCPs) or at Study Centers. A Data Safety Monitoring Board&#xD;
      (DSMB) will review unblinded results for an interim analysis when 20 subjects have completed&#xD;
      12 months of drug. This review will focus on adverse events and efficacy results. Subjects&#xD;
      will be monitored for the development of new SEBs after they discontinue study treatment. At&#xD;
      the end of the 18 months, given that the observed adverse events are minimal, patients on&#xD;
      placebo will be offered the opportunity to take GDC-0449 for 18 months in an open label&#xD;
      continuation, followed by six months observation, and patients on GDC449 will be monitored&#xD;
      for the next 24 months for assessment of the duration of benefit after stopping the drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of New Surgically Eligible Basal-cell Carcinomas</measure>
    <time_frame>3 months of receiving study drug</time_frame>
    <description>Number of new surgically eligible basal-cell carcinomas per patient per year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment</measure>
    <time_frame>These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.</time_frame>
    <description>The number of new surgically eligible basal-cell carcinomas per patient per month is reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Basal Cell Nevus Syndrome</condition>
  <condition>Gorlin Syndrome</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDC-0449</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vismodegib 150MG by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0449</intervention_name>
    <description>capsule, 150 mg, one pill daily, 18 months</description>
    <arm_group_label>GDC-0449</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Hedgehog Inhibitor</other_name>
    <other_name>Hedgehog Antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subject:&#xD;
&#xD;
          -  has had diagnosed at least 10 SEB (of diameter 3 mm diameter or greater on the nose or&#xD;
             periorbital skin, 5 mm or greater elsewhere on the face, or 9 mm or greater on&#xD;
             non-facial areas excluding the skin below the knees) during the two years before study&#xD;
             entry, as documented histologically in physicians' records and/or diagnosed clinically&#xD;
             by a Study Investigator at baseline.&#xD;
&#xD;
          -  meet diagnostic criteria for basal cell nevus syndrome&#xD;
&#xD;
          -  is willing to abstain from application of non-study topical medications to the skin&#xD;
             for the duration of the study, including prescription and over the counter&#xD;
             preparations. Subjects will be encouraged to use sunscreen (SPF 15) at least once&#xD;
             daily on all exposed skin sites.&#xD;
&#xD;
          -  is willing to forego treatment of BCCs unless the BCCs are documented by Study&#xD;
             Investigators, preferably on two separate visits, except when the PSCP believes that&#xD;
             delay in treatment potentially might compromise the health of the subject.&#xD;
&#xD;
          -  has normal laboratory tests as defined by the following: Normal hematopoietic&#xD;
             capacity, Normal hepatic function: AST and ALT greater than or equal to 2x the upper&#xD;
             limit of normal (ULN) Total bilirubin within normal range 0.20 mg/dl to 1.50 mg/dl or&#xD;
             within 3x ULN for patients with Gilbert's disease Normal renal function: normal serum&#xD;
             creatinine or measured creatinine clearance less than 50 mL/minute. Fasting&#xD;
             cholesterol greater than or equal to 220 untreated&#xD;
&#xD;
          -  be willing to not donate blood or semen for three months following discontinuation of&#xD;
             Study medications.&#xD;
&#xD;
          -  is willing to avoid pregnancy in his partner as defined by the following: Male subject&#xD;
             is willing to use a latex condom during the study and for 3 months after the last dose&#xD;
             during sexual contact with a female of childbearing potential, even if he has had a&#xD;
             successful vasectomy. His partner must also use a form of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject:&#xD;
&#xD;
          -  has used topical or systemic therapies that might interfere with the evaluation of the&#xD;
             study medication during the study. Specifically these include the use of: (i)&#xD;
             glucocorticoids to more than 5% of the skin (ii) retinoids systemically or topically&#xD;
             to more than 5% of the skin during the six months prior to study entry; (iii)&#xD;
             alpha-hydroxy acids to more than 5% of the skin during the six months prior to study&#xD;
             entry (iv) 5-fluorouracil or imiquimod systemically or topically to the skin above the&#xD;
             knees during the six months prior to study entry. (v) treatment with systemic&#xD;
             chemotherapy within one year prior to starting study medication.&#xD;
&#xD;
          -  has a history of hypersensitivity to any of the ingredients in the study medication&#xD;
             formulations.&#xD;
&#xD;
          -  is unable to return for follow-up visits and tests.&#xD;
&#xD;
          -  has uncontrolled systemic disease, including known HIV positive patients.&#xD;
&#xD;
          -  has history of congestive heart failure.&#xD;
&#xD;
          -  has uncontrolled hypocalcemia, hypomagnesemia, or hypokalemia&#xD;
&#xD;
          -  has clinically important history of liver disease, including viral or hepatitis,&#xD;
             current alcohol abuse, or cirrhosis.&#xD;
&#xD;
          -  has any condition or situation which in the Investigator's opinion may put the subject&#xD;
             at significant risk, could confound the study results, or could interfere&#xD;
             significantly with the subject's participation in the study.&#xD;
&#xD;
          -  has a history of invasive cancer within the past five years excluding non-melanoma&#xD;
             skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or CLL&#xD;
             Stage 0.&#xD;
&#xD;
          -  has current, recent (within 4 weeks of Day 1), or planned participation in an&#xD;
             experimental drug study while enrolled in this study.&#xD;
&#xD;
          -  is a female who is pregnant, plans to ever to become pregnant, capable of becoming&#xD;
             pregnant or is breast feeding.&#xD;
&#xD;
          -  is a male who is unwilling or unable to comply with pregnancy prevention measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ervin Epstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Oakland Research Institiute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.</citation>
    <PMID>22670904</PMID>
  </results_reference>
  <results_reference>
    <citation>Ally MS, Tang JY, Joseph T, Thompson B, Lindgren J, Raphael MA, Ulerio G, Chanana AM, Mackay-Wiggan JM, Bickers DR, Epstein EH Jr. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. JAMA Dermatol. 2014 May;150(5):542-5. doi: 10.1001/jamadermatol.2013.7444.</citation>
    <PMID>24623282</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, Epstein EH Jr. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.</citation>
    <PMID>27838224</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
        <group group_id="P2">
          <title>GDC-0449</title>
          <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Start</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Reallocated to or Continued Vismodegib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
        <group group_id="B2">
          <title>GDC-0449</title>
          <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="8"/>
                    <measurement group_id="B2" value="54" spread="8"/>
                    <measurement group_id="B3" value="54" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of New Surgically Eligible Basal-cell Carcinomas</title>
        <description>Number of new surgically eligible basal-cell carcinomas per patient per year</description>
        <time_frame>3 months of receiving study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
          <group group_id="O2">
            <title>GDC-0449</title>
            <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Surgically Eligible Basal-cell Carcinomas</title>
          <description>Number of new surgically eligible basal-cell carcinomas per patient per year</description>
          <units>events per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="1.32"/>
                    <measurement group_id="O2" value="2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period</title>
        <time_frame>Baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
          <group group_id="O2">
            <title>GDC-0449</title>
            <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period</title>
          <units>Millimeters</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="NA" upper_limit="NA">The PI has left the institution and the only access to the data is from the publication. The records no longer exist. All efforts have been made to obtain the data.</measurement>
                    <measurement group_id="O2" value="-60" lower_limit="NA" upper_limit="NA">The PI has left the institution and the only access to the data is from the publication. The records no longer exist. All efforts have been made to obtain the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment</title>
        <description>The number of new surgically eligible basal-cell carcinomas per patient per month is reported.</description>
        <time_frame>These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.</time_frame>
        <population>The incidence of new surgically eligible basal-cell carcinomas after stopping vismodegib was analysed in an exploratory analysis of the patients who crossed over to vismodegib and were followed up for at least 6 months after stopping vismodegib (n=5).</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
          <group group_id="O2">
            <title>GDC-0449</title>
            <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment</title>
          <description>The number of new surgically eligible basal-cell carcinomas per patient per month is reported.</description>
          <population>The incidence of new surgically eligible basal-cell carcinomas after stopping vismodegib was analysed in an exploratory analysis of the patients who crossed over to vismodegib and were followed up for at least 6 months after stopping vismodegib (n=5).</population>
          <units>carcinomas per patient per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.5"/>
                    <measurement group_id="O2" value="0.06" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Grade 1 and 2 events are listed if considered related to vismodegib treatment. All other graded events are listed.&#xD;
The PI has left the institution and the only access to the data is from the publication, in which the data are reported as presented here. The records no longer exist. All efforts have been made to obtain the data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>placebo pill by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
        <group group_id="E2">
          <title>GDC-0449</title>
          <description>vismodegib 150MG by mouth once daily&#xD;
GDC-0449: capsule, 150 mg, one pill daily, 18 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac stent for blocked artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mesenteric cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Reactions to antibiotic</sub_title>
                <description>Reactions to antibiotics include ciprofloxacin and Bactrim</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hip replacement surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Knee replacement surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastrointestinal upset</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ervin H Epstein Jr., MD</name_or_title>
      <organization>Children's Hospital of Oakland Research Institute, Oakland</organization>
      <phone>510-450-5688</phone>
      <email>eepstein@chori.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

